Lee Ainslie Novo Nordisk A S Transaction History

Maverick Capital LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$122.71 - $146.91 $704,846 - $843,851	5,744 Added 272.87%	7,849 $1.12 Million
Q1 2024 May 15, 2024	BUY	$102.11 - $135.92 $214,941 - $286,111	2,105 New	2,105 $270,000
Q1 2023 May 15, 2023	SELL	$132.34 - $159.14 $19,586 - $23,552	-148 Reduced 6.42%	2,156 $343,000
Q4 2022 Feb 14, 2023	SELL	$102.55 - $135.33 $17,536 - $23,141	-171 Reduced 6.91%	2,304 $311,000
Q3 2022 Nov 14, 2022	BUY	$95.28 - $116.93 $235,818 - $289,401	2,475 New	2,475 $247,000
Q1 2021 May 17, 2021	SELL	$67.06 - $75.82 $178,245 - $201,529	-2,658 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$63.89 - $73.8 $400,909 - $463,095	-6,275 Reduced 70.25%	2,658 $186,000
Q3 2020 Nov 16, 2020	BUY	$63.69 - $70.22 $568,942 - $627,275	8,933 New	8,933 $620,000

1,954

320M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $232B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.